Watson W P, Little H J
Pharmacology Department, Medical School, University Walk, Bristol, UK.
Psychopharmacology (Berl). 1994 Mar;114(2):321-8. doi: 10.1007/BF02244855.
Unlike the dihydropyridine calcium channel antagonists studied previously, the benzothiazepine calcium channel antagonist, diltiazem, increased the incidence of convulsions caused by bicuculline, N-methyl-DL-aspartate or 4-aminopyridine. However, the latencies to convulsions were also increased. Diltiazem increased the ratings of convulsive behaviour on handling after intraperitoneal administration of bicuculline, or pentylenetetrazol and after the calcium channel activator, Bay K 8644, administered ICV. When the binding of the dihydropyridine, [3H]-nitrendipine in the CNS was measured in vivo, this was increased by diltiazem. This compound therefore showed a different pattern of interaction with convulsant drugs then that previously demonstrated for other calcium channel antagonists, appearing to possess both pro- and anticonvulsant actions, and a different pattern of interaction with the dihydropyridine receptor complex.
与之前研究的二氢吡啶类钙通道拮抗剂不同,苯并硫氮䓬类钙通道拮抗剂地尔硫䓬会增加荷包牡丹碱、N-甲基-DL-天冬氨酸或4-氨基吡啶所致惊厥的发生率。然而,惊厥发作的潜伏期也会延长。地尔硫䓬会提高腹腔注射荷包牡丹碱、戊四氮后以及经脑室内注射钙通道激活剂Bay K 8644后处理时的惊厥行为评分。当在体内测量中枢神经系统中二氢吡啶类药物[3H]-尼群地平的结合时,地尔硫䓬会使其增加。因此,该化合物与惊厥药物的相互作用模式不同于之前其他钙通道拮抗剂所表现出的模式,似乎兼具促惊厥和抗惊厥作用,并且与二氢吡啶受体复合物的相互作用模式也不同。